SurinameTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.011 (0.011–0.012) 2.1 (2–2.2)
Mortality (HIV+TB only) 0.011 (<0.01–0.014) 2 (1.5–2.7)
Prevalence  (includes HIV+TB) 0.24 (0.13–0.38) 44 (24–71)
Incidence  (includes HIV+TB) 0.2 (0.17–0.25) 38 (31–46)
Incidence (HIV+TB only) 0.064 (0.052–0.077) 12 (9.6–14)
         
Case detection, all forms (%) 71 (59–87)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 11 (6.1–17)
MDR-TB cases among notified pulmonary
TB cases
3 (1–4) 2 (1–3)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 100   4
Pulmonary, clinically diagnosed 16   0
Extrapulmonary 26   0
       
Total new and relapse 146    
Previously treated, excluding relapses 12    
Total cases notified 158    
Among 149 new and relapse cases:
7 (5%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 88 (88%) 13 (81%) 102
Laboratory-confirmed RR-/MDR-TB cases     9
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 154 (97)
HIV-positive TB patients 44 (29)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 27 (61)
HIV-positive TB patients on antiretroviral therapy (ART) 32 (73)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (77) 136
Previously treated cases, excluding relapse, registered in 2013 (20) 5
HIV-positive TB cases, all types, registered in 2013 (65) 31
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 9.3
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-26 Data: www.who.int/tb/data